This observational cohort study reports the short-and long-term clinical outcomes of 31 patients admitted for acute nonmalignant, non-cirrhotic portal vein thrombosis (PVT) over a 10-year period. Patients had a mean age of 43 years at admission and a mean duration of followup of 84 months. All patients were initially treated with anticoagulants. Complete recanalization occurred within 30 days after admission in 18 patients (58%), partially in nine patients (29%), and failed in four patients (13%). During follow-up, 10 patients (32%) had at least one episode of gastrointestinal bleeding. The probability of remaining bleed-free was 0.93 at 24 months and 0.61 at 48 months. Fundal varices were not controlled by endoscopic sclerotherapy, so all four patients underwent portosystemic shunt construction. To date, there has been no mortality. In conclusion, using a combination of different treatment options reduces the risk of death and late complications in patients with nonmalignant, non-cirrhotic PVT.
Introduction
Portal vein thrombosis (PVT) is the second most common cause of portal hypertension after cirrhosis in the developed world. 1 As far as treatment and prognosis are concerned, it is important to distinguish between cirrhotic and non-cirrhotic PVT. The natural history of cirrhotic PVT differs from other causes, is largely influenced by the severity of liver disease and is associated with the occurrence of hepatocellular carcinoma. 2 When PVT results from underlying malignant disease, the prognosis is mainly determined by the extent of progression of the primary tumour.
Portal vein thrombosis in the absence of cirrhosis is rare. In patients with nonmalignant, non-cirrhotic, extrahepatic PVT, the disease may be the result of concomitant local, acquired and inherited thrombophilic disorders. 3 In about one-third of patients the aetiology is unknown. 4 In the absence of cirrhosis, liver function is usually well preserved; however, the significant portal hypertension may result in serious lifethreatening complications including variceal bleeding, intestinal venous congestion and ischaemia, as well as ascites. 4 -6 There is no established management algorithm for N Kobilica, M Skalicky, F Milotič et al.
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patients with PVT and its management has been complicated by a lack of randomized controlled trials, the clinical difficulty of distinguishing acute from more chronic disease, and the perceived risks associated with anticoagulant therapy. For recent-onset PVT, case studies and prospective multicentre follow-up studies suggest that early anticoagulation may result in recanalization in over 80% of cases. 7 -10 This approach is more controversial when the patient has long standing PVT and/or cavernomas. The natural history of chronic PVT is poorly defined. Current therapeutic measures are directed at the prevention of variceal bleeding and symptom control. There is, however, no consensus about the efficacy of different modes of medical and/or invasive treatment in the management of long standing PVT. 4, 6, 11 The aim of the present study was to describe the short-and long-term clinical outcomes of patients admitted to the Department of Vascular Surgery, University Clinical Centre Maribor, Maribor, Slovenia, for acute non-malignant, non-cirrhotic PVT over a 10-year period.
Patients and methods

PATIENTS AND STUDY DESIGN
This was an observational cohort study. From January 1997 to December 2006, patients with extrahepatic PVT admitted to the Department of Vascular Surgery, University Clinical Centre Maribor, were enrolled sequentially. Of these, patients with acute non-malignant, non-cirrhotic PVT were included in the study. Patients were excluded if they had cirrhosis or malignancies.
The study protocol was approved by the Scientific Research Board of the Surgical Clinic, University Clinical Centre Maribor. Written informed consent was obtained from all patients participating in the study.
CLINICAL INVESTIGATIONS
Portal vein thrombosis was confirmed by spiral computed angiography (Toshiba-Aquilion 64; Toshiba, Tokyo, Japan) and/or magnetic resonance imaging (MR-Signa Excite HD; General Electric Co., Cincinnati, OH, USA) and Doppler sonography, used with colour and power Doppler (Toshiba-Aplio XG; Toshiba). Liver cirrhosis was excluded by morphological and clinical findings. Specifically, patients with biopsyproven cirrhosis or patients with clinical, laboratory, or imaging evidence of chronic liver disease were excluded. Age of the thrombosis was estimated by the clinical history, when possible. Thrombus was arbitrarily defined as new if there was a recent episode of abdominal pain associated with radiological findings of PVT, with no evidence of chronic portal hypertension and absent portal collaterals on cross-sectional imaging.
Hepatocellular carcinoma was ruled out by abdominal ultrasound, spiral abdominal computed tomography and α-fetoprotein determination. Upper endoscopy was undertaken to look for the signs of portal hypertension and the findings were evaluated according to the grading system of the North Italian Endoscopic Club. 12 A history of known thrombophilic risk factors (familial thrombophilia, previous venous thrombosis, abdominal surgery, abdominal trauma or sepsis, contraceptive use, overt myeloproliferative disorders) was taken for all patients with PVT. Screening for thrombophilia was completed with the following investigations: protein C and antithrombin III, total and free protein S antigen, anticardiolipin antibodies, fasting plasma homocysteine and lupus anticoagulant. The mutation of factor V (factor V Leiden) and the 20210G-A mutation of the prothrombin gene were N Kobilica, M Skalicky, F Milotič et al. Follow-up of patients with portal vein thrombosis identified, as previously described. 13 Portal vein thrombosis was classified into one of four anatomical categories: (i) thrombosis confined to the portal vein beyond the confluence of the splenic and superior mesenteric vein (SMV); (ii) extension of thrombus into the SMV, but with patent mesenteric vessels; (iii) diffuse thrombosis of the splanchnic venous system, but with large collaterals; and (iv) extensive splanchnic venous thrombosis, but with only fine collaterals. 14 PVT was classified as complete or partial if the thrombus resulted in an absence or reduction of blood flow in the main portal trunk, left and right lobar branches, SMV and splenic vein, respectively. The thrombus was defined as an occluding thrombus when occupying > 90% of the circumference of the vessel. The presence of a portal cavernoma was investigated. Primary PVT was defined as a thrombosis of a portal vein that was not associated with any other disease or aetiological factor. The term secondary PVT was defined as a thrombosis associated with any condition known to be a predisposing factor for PVT. 3
PATIENT MANAGEMENT
All patients were initially treated with anticoagulants, prophylactic antibiotic therapy and i.v. fluid administration as soon as they were diagnosed with PVT. Immediate systemic anticoagulation with an i.v. bolus of unfractionated heparin was initiated as 5000 IU/5 ml (Krka dd, Novo mesto, Slovenia), followed by lowmolecular-weight heparin ( 
PATIENT FOLLOW-UP
Doppler sonography combined with colour and power Doppler was used to evaluate disease progression in patients at 3-month intervals during the first year and from then onwards at 6-month intervals. When necessary, computed tomography angiography or nuclear magnetic resonance examinations were repeated.
VARICEAL BLEEDING
Variceal bleeding or rebleeding was defined according to the Baveno IV Consensus Workshop. 15 Rebleeding was defined according to the Baveno II consensus 16 as evidence of any bleeding occurring at least 48 h after admission. Variceal eradication was defined as non-visualization of varices, or grade I varices.
STATISTICAL ANALYSES
Endpoints of the study were death by any cause, death from gastrointestinal bleeding and gastrointestinal bleeding. Statistical analysis was performed using STATISTICA software, version 9.0 (StatSoft, Tulsa, OK, USA). Risk of gastrointestinal bleeding was described using a Kaplan-Meier plot; 95% confidence intervals (95% CI) for probabilities were calculated according to Simon. 17 For categorical variables, Pearson's χ 2 -test was performed unless exact methods were required for frequency tables, which occurred when > 20% of events had an expected frequency of less than five cases. A N Kobilica, M Skalicky, F Milotič et al. Follow-up of patients with portal vein thrombosis value of P < 0.10 was considered to be statistically significant due to the small number of cases.
Results
PATIENT POPULATION
From January 1997 to December 2006, 75 patients with extrahepatic PVT were enrolled. Of these, 31 patients with acute nonmalignant, non-cirrhotic PVT were included in the study. Seventeen patients were excluded because of cirrhosis and 27 patients because of malignancies. Data are presented for a cohort of 14 males and 17 females with a mean age at admission of 43 years (range 18 -57 years). The mean duration of follow-up was 84 months (range 24 -118 months).
SYMPTOMS AND SIGNS AT ADMISSION
Twelve patients were admitted from other institutions within 6 days of symptom development. All other patients were admitted through the Emergency Department of the University Clinical Centre Maribor. The duration of symptoms in the latter group was 48 -72 h. The most frequent symptom on presentation was abdominal pain (21/31, 68%). None of the patients presented with peritoneal signs. Other common symptoms on presentation included diarrhoea (9/31, 29%), nausea and vomiting (9/31, 29%), lower gastrointestinal bleeding (2/31, 6%), and malaise and upper gastrointestinal bleeding (3/31, 10%).
CONDITIONS ASSOCIATED WITH THROMBOSIS
A total of 13 (42%) patients had primary PVT and 18 (58%) patients had secondary PVT. The prevalence of known thrombogenic risk factors in the patients with secondary PVT are presented in Table 1 ; three of the 18 patients with secondary PVT (17%) had antithrombin III deficiency as a thrombogenic risk factor.
EXTENT OF THROMBOSIS
The portal trunk was involved in 28 patients and its occlusion was complete in all 28 cases. Mesenteric vein and splenic vein thrombosis coexisted with PVT in 12 and six patients, respectively. In three patients, mesenteric and splenic vein thrombosis caused partial occlusion of the proximal part of the portal vein.
PATIENT MANAGEMENT
All patients were initially treated with anticoagulants, antibiotics and total parenteral nutrition as soon as they were diagnosed with PVT, as described in the Patients and Methods. The duration of anticoagulation with warfarin was 6 months (with a maintenance international normalized ratio [INR] of 2 -3) in all patients, except in the three patients with antithrombin III deficiency in whom warfarin was administered on a continuous basis. A total of 10 patients were treated with a β-adrenergic blocking agent (propranolol;
Lek, Ljubljana, Slovenia), four of whom were already being treated with such agents for the prevention of variceal bleeding at the time of the index variceal bleed. The starting dose of propranolol was 10 mg/day and the dose was titrated to reduce the resting heart rate by 25%; therapy was maintained indefinitely. 
OUTCOME OF RECANALIZATION
Complete recanalization occurred within 30 days after admission in 18 patients (58%), was partial in nine patients (29%) and failed in four patients (13%) ( Table 2 ).
COMPLICATIONS
Cavernous transformation of the portal vein developed within 3 months in 11 patients (35%). During follow-up, 10 patients (32%) developed portal hypertension with variceal bleeding. One patient developed ascites. There was no variceal bleeding in the group with antithrombin III deficiency, in whom continuous anticoagulation with warfarin was administered. There was also no variceal bleeding in the group of patients with complete initial recanalization following anticoagulant therapy.
VARICEAL BLEEDING
During follow-up, 10 patients had at least one episode of gastrointestinal bleeding. In six patients, the first variceal bleed was caused by oesophageal varices and, in four patients, it was caused by fundal gastric varices.
Variceal eradication was accomplished in four of the patients who had oesophageal varices. In the other two patients with oesophageal varices, variceal eradication was not accomplished and both patients had grade II varices at the last follow-up visit. None of the patients with oesophageal varices developed a recurrence of variceal bleeding, although five of these patients experienced more than one episode of bleeding: three patients had two episodes of bleeding and two patients had three episodes.
In the group of patients with fundal gastric varices, all four patients experienced three episodes of massive bleeding (all four patients had no recanalization of PVT and splenic vein thrombosis). Bleeding in this group of patients was poorly controlled by endoscopic sclerotherapy or endoscopic variceal ligation and all four patients eventually underwent (after their third bleed) an elective portosystemic shunt construction. In all four patients with fundal gastric varices, splenic vein thrombosis coexisted with PVT.
The probability of remaining bleed-free (censored by index bleeding) was 0.93 (95% CI 0.81, 0.99) at 24 months and 0.61 (95% CI 0.44, 0.80) at 48 months (Fig. 1 ).
SHUNTS
Portosystemic shunt construction (mesenterico-renal with vein interposition graft) was performed in five patients for the following reasons: variceal rebleeding (n = 4); refractory ascites (n = 1).
CLINICAL OUTCOME
To date, none of the patients has died. In shunted patients, no rebleeding episode was observed (median follow-up 48 months, range 24 -84 months) and the condition has disappeared in one patient with ascites.
Discussion
The present study investigated the short-and long-term clinical outcomes of patients 4,6,9 -11,18,19 In the acute stage of the disease, the question of anticoagulation in patients with PVT is a crucial one. 9, 10 There are no randomized trials of its use in different patterns of PVT. The effectiveness of anticoagulation in patients with evidence of acute PVT has been shown in a number of small studies, case reports and multicentre follow-up studies. 7, 10, 20 Although the rate of spontaneous recovery of vein patency is not known, these studies suggest that anticoagulation may result in recanalization in > 80% of cases. 7, 10, 20 Among patients in the present study, complete recanalization occurred in 18 (58%), however, in the remaining patients, clinical symptoms resolved and there were no severe early complications such as intestinal gangrene or With no treatment at all, recanalization is rare. 7, 21, 22 Since the duration or degree of anticoagulation has not been standardized, 9 -11 we chose to adopt the management algorithm as applied to deep vein thromboses in the lower limb. 23 Where a self-limiting cause for acute PVT has been identified (e.g. infection, acute pancreatitis) or where risk factors could be eliminated (use of oral contraceptives), a finite coumarin anticoagulation course of 3 -6 months has been suggested. 7, 11, 19 In patients with an identified ongoing prothrombotic tendency, there may be an advantage in continuous anticoagulation. In the present study, the duration of anticoagulation with warfarin was 6 months (with a maintenance INR of 2 -3) in all patients, except in the three patients with antithrombin III deficiency, where it was administered on a continuous basis. None of the latter patients developed long-term complications or experienced variceal bleeding. The number of patients was, however, too small to allow the recommendation that patients with incomplete or no recanalization of PVT should receive life-long coumarin-type drug treatment.
Data are insufficient to allow reliable estimates of the risk-benefit indices for the more aggressive treatment approaches in acute PVT based on systemic administration of thrombolytic agents, transjugular intrahepatic portosystemic shunts or surgical thrombectomy. 5, 24 In a retrospective study of 20 patients with recent PVT, transcatheter thrombolysis was beneficial in avoiding patient death or avoiding bowel resection, however there was a high complication rate. 24 In patients where initial therapy with heparin fails there may be an advantage in thrombolytic treatment. 22 Nonetheless, there is no real consensus on whether initial thrombolysis should be given in preference to anticoagulation.
There is also no real consensus on the use of anticoagulation therapy when the patient has long-standing PVT or cavernoma. 25 The use of anticoagulant therapy in a study by Condat et al. 26 was associated with a significant reduction in new thrombotic episodes and there was no difference in the bleeding rate between those patients taking, or not taking, anticoagulants. In their study, there was also no bleeding-related death in patients on warfarin. 26 The risk of death from gastrointestinal bleeding remains a serious threat according to the majority of published studies of long-term PVT followup. Bleeding oesophageal varices account for 2 -10% of deaths, 4, 27, 28 although in some studies there were no deaths because of variceal bleeding. 10 The development of different collateral vessels, their location and efficiency may explain the observed differences. 10 Serious rebleeding episodes in the present study were connected with the presence of fundal varices, absence of recanalization and the extension of the thrombosis into the splenic vein. In general, the endoscopic treatment of variceal bleeding was successful. Contrary to another report on the treatment of non-malignant, non-cirrhotic PVT variceal bleeding with endoscopy, 6 fundal varices in the present study were extremely difficult to eradicate. Although the group of patients receiving β-adrenergic blockers as secondary prophylaxis in the cohort was small, these agents did not reduce the risk of bleeding in patients with fundal varices, so their widespread use for secondary prophylaxis remains questionable.
Although good results from portosystemic shunting for extrahepatic PVT have been reported from dedicated units, 29 the earlier reports of high mortality in surgical patients • Received for publication 17 January 2011 • Accepted subject to revision 31 January 2011
• Revised accepted 7 April 2011 Copyright © 2011 Field House Publishing LLP has led to a broad consensus that shunt surgery for PVT has a small role to play. 4, 11, 18 Those reports were, however, in cirrhotic patients, where the relatively high surgical mortality could probably be attributed to the progressive nature of the deterioration in liver function. We believe that, in patients with an intact liver function, a switch to a decompressive surgical shunt procedure is mandatory if endoscopic therapy fails to control recurrent variceal haemorrhage. 30 Several types of surgical shunt have been tested for the treatment of portal hypertension, but it remains unclear which type is the best to use. There have been several controlled studies comparing distal splenorenal shunts with non-selective shunts, none of which have demonstrated a survival advantage for either type of procedure. 30, 31 We prefer to use smalldiameter superior mesenteric left renal vein shunting with autogenous saphenous vein as the interposition conduit. This is not a selective decompression; however, it is not technically difficult to perform and the risk of encephalopathy and postoperative mortality is minimal in patients with preserved liver function. There were no complications in the present study and, to date, there has been no mortality. All patients with shunts are still bleed-free. We believe that, in selected patients with nonmalignant, non-cirrhotic PVT, shunt surgery reduces the risk and anxiety of bleeding, repeated endoscopies, β-blocker side-effects and financial burden on society.
In conclusion, the present short-and longterm follow-up study demonstrated that the use of a combination of different treatment options minimized both the risk of death and late complications in patients with nonmalignant, non-cirrhotic PVT.
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